Cargando…

Pharmacokinetics of intravenous administered two different high doses of ascorbic acid in healthy beagle dogs

OBJECTIVE: We performed a randomized two-way crossover study to evaluate the pharmacokinetic profiles of two high-dose ascorbic acid (AA) after IV infusion in healthy beagle dogs. MATERIALS AND METHODS: The dogs were administered IV AA at two doses of 1.5 and 3 gm/kg for 4 h, and the AA concentratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Seula, Oh, Ye-In, Jeong, Jong-Woo, Song, Kun-Ho, Koo, Tae-Sung, Seo, Kyoung-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: A periodical of the Network for the Veterinarians of Bangladesh (BDvetNET) 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882724/
https://www.ncbi.nlm.nih.gov/pubmed/31819875
http://dx.doi.org/10.5455/javar.2019.f371
Descripción
Sumario:OBJECTIVE: We performed a randomized two-way crossover study to evaluate the pharmacokinetic profiles of two high-dose ascorbic acid (AA) after IV infusion in healthy beagle dogs. MATERIALS AND METHODS: The dogs were administered IV AA at two doses of 1.5 and 3 gm/kg for 4 h, and the AA concentration in plasma and urine pH was measured before and after administration. RESULTS: The plasma concentrations of AA in both groups peaked 3 h after administration. Among the two groups, the urine pH was not significantly different (p = 0.1299–0.7944). High-dose IV AA did not induce serious adverse events in dogs. CONCLUSION: The results of this study suggest that the high dose of AA which reaches the therapeutic dose for cancer and supports the safety of high-dose IV AA in dogs.